Utility of

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: James Carr, David Casalino, Austin Ho, Mary Kate Keeter, Masha Kocherginsky, Eric V Li, Margarita Mana-Ay, Hiten D Patel, Sai Kaushik Shankar Ramesh Kumar, Ashley E Ross, Hatice Savas, Edward M Schaeffer, Mariavittoria Vescovo, Ximing J Yang, Ruoji Zhou

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: Germany : European journal of nuclear medicine and molecular imaging , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 5231

PURPOSE: PSMA PET offers the potential for improved local staging prior to radical prostatectomy (RP). We evaluated PSMA PET versus mpMRI for local and nodal staging for patients with localized NCCN high or very high risk prostate cancer undergoing RP. METHODS: A prospective single center pilot study was conducted from 9/2018 to 6/2022. Patients underwent both mpMRI and RESULTS: At RP, 79% (38/48) had EPE, 31% had SVI, and 31% had LNI. At the patient level for EPE, PSMA PET had similar sensitivity (65.8% vs. 84.2%, respectively, P = 0.07) but higher specificity (80% vs. 40%, P = 0.045) compared to mpMRI, respectively. For SVI, PSMA PET had lower sensitivity (62.5% vs. 87.5%, P = 0.046) and similar specificity (87.5% vs. 90.6%, P = 0.56). For side-specific LNI, PSMA PET had higher sensitivity (50% vs. 25%, P = 0.03) and similar specificity (96.1% vs. 94.7%, P = 0.71) compared to mpMRI. CONCLUSION: PSMA PET offers higher specificity for EPE and higher sensitivity for LNI compared to mpMRI. PSMA PET may improve overall surgical planning, and may be combined with diagnostic mpMRI and clinicopathological variables through nomograms to further predict EPE, SVI, or LNI. CLINICAL TRIAL REGISTRATION: NCT03392181 https://clinicaltrials.gov/study/NCT03392181 .
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH